Delayed attainment of full donor chimaerism following alemtuzumab-based reduced-intensity conditioning haematopoeitic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes is associated with improved outcomes.

Lim, Zi Yi

Delayed attainment of full donor chimaerism following alemtuzumab-based reduced-intensity conditioning haematopoeitic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes is associated with improved outcomes. [electronic resource] - British journal of haematology Aug 2007 - 517-26 p. digital

Publication Type: Journal Article

0007-1048

10.1111/j.1365-2141.2007.06676.x doi


Adult
Aged
Alemtuzumab
Antibodies, Monoclonal--therapeutic use
Antibodies, Monoclonal, Humanized
Antibodies, Neoplasm--therapeutic use
Antineoplastic Agents--therapeutic use
Disease-Free Survival
Female
Follow-Up Studies
Hematopoietic Stem Cell Transplantation
Histocompatibility Testing
Humans
Leukemia, Myeloid, Acute--mortality
Male
Middle Aged
Myelodysplastic Syndromes--mortality
Prospective Studies
Time Factors
Transplantation Chimera
Transplantation Conditioning--methods
Transplantation, Homologous
Treatment Outcome